💰 Peptide Startup Funding Dynamics
A comprehensive overview of global peptide startup funding from 2022–2025, covering funding rounds, amounts, investors, and hot-sector analysis. GLP-1, oral delivery, and PDC are the most capital-attractive segments. This chapter provides funding case studies, investment firm rankings, valuation analysis, and exit case studies.
1. 2022–2025 Key Funding Cases
| Company |
Region |
Round |
Amount |
Lead Investors |
Focus Area |
Year |
| Bicycle Therapeutics |
UK |
Public Follow-on |
$555M |
Multiple institutions |
Bicyclic peptide platform + oncology PDC |
2024 |
| Orbital Therapeutics |
US |
Series A |
$270M |
a16z, Arch Venture |
Cyclic peptide + RNA conjugate delivery |
2025 |
| Eccogene |
China |
Series B |
$200M |
Beta Pharma, etc. |
Oral GLP-1 innovative drug |
2024 |
| Zealand Pharma |
Denmark |
Private Placement |
$500M |
Multiple institutions |
GLP-1/GCG dual target |
2024 |
| Vicinitas Therapeutics |
US |
Series B |
$175M |
Pfizer Ventures |
Cyclic peptide targeted protein degradation |
2024 |
| Recbio |
China |
Series C |
¥1.5B |
Multiple funds |
Peptide vaccine |
2023 |
| Sciwind Biosciences |
China |
IPO |
$1.2B (market cap) |
Nasdaq |
Oral GLP-1 API |
2023 |
| Metsera |
US |
Series A+B |
$350M |
Arch, GV |
GLP-1 combination therapy |
2024 |
| Bolt Biotherapeutics |
US |
Series C |
$150M |
Multiple |
Immunostimulatory PDC |
2023 |
| Kinaset Therapeutics |
US |
Series A |
$115M |
5AM Ventures, etc. |
Peptide inhaled formulation |
2023 |
| LTD Pharma |
China |
Series B |
¥800M |
Qiming Venture Partners |
Oral peptide delivery platform |
2024 |
| Protagonist Therapeutics |
US |
Partnership + Financing |
$325M |
J&J collaboration |
Oral cyclic peptide IL-23 |
2023 |
| PepGen |
US |
IPO |
$108M |
Multiple |
Peptide oligonucleotide delivery |
2023 |
| Amgenx |
China |
Series A |
¥500M |
Matrix Partners China |
Cosmetic peptide raw materials |
2024 |
| SanoRNA |
China |
Pre-IPO |
¥1.0B |
Multiple |
Peptide nucleic acid conjugate |
2024 |
| Nimbus Therapeutics |
US |
Follow-on |
$210M |
Multiple |
Peptide inhibitor |
2024 |
| Circle Pharma |
US |
Series C |
$95M |
Nextech, etc. |
Oral cyclic peptide macrocycle |
2024 |
| Borealis Biosciences |
US |
Series A |
$150M |
Versant, Novartis |
Peptide kidney disease drug |
2025 |
| DingPeptide |
China |
Series B |
¥600M |
Sequoia Capital China |
GLP-1 biosimilar |
2024 |
| Pioneer Peptide |
China |
Series A |
¥300M |
Hillhouse Capital |
Peptide CDMO + conjugate |
2024 |
2. Investment Firm Activity Ranking
| Rank |
Investment Firm |
Headquarters |
Peptide Deals (2022–2025) |
Key Investment Sectors |
Representative Deals |
| 1 |
Arch Venture Partners |
US |
12 |
GLP-1, cyclic peptide platforms |
Orbital, Metsera |
| 2 |
a16z (Andreessen Horowitz) |
US |
8 |
Cyclic peptide+RNA, oral delivery |
Orbital |
| 3 |
Sequoia Capital China |
China |
7 |
GLP-1, CDMO |
DingPeptide, SENO partnership |
| 4 |
Qiming Venture Partners |
China |
6 |
Oral delivery, peptide vaccine |
LTD Pharma |
| 5 |
Versant Ventures |
US |
5 |
Cyclic peptide, kidney disease peptides |
Borealis Biosciences |
| 6 |
Nextech Invest |
US |
4 |
Oral cyclic peptides |
Circle Pharma |
| 7 |
Pfizer Ventures |
US |
4 |
Targeted protein degradation |
Vicinitas |
| 8 |
GV (Google Ventures) |
US |
3 |
GLP-1 combination therapy |
Metsera |
| 9 |
Beta Pharma Industrial Capital |
China |
3 |
GLP-1 innovative drugs |
Eccogene |
| 10 |
Hillhouse Capital |
China |
3 |
CDMO, conjugate drugs |
Pioneer Peptide |
3. Hot-Sector Analysis (by Funding Amount)
| Sector |
2023–2025 Total Funding (Est.) |
Number of Deals |
Typical Deal Size |
Investment Heat |
| GLP-1 Analogues (incl. oral) |
~$1.8B |
18 |
$50M–$500M |
🔥🔥🔥🔥🔥 |
| Oral Peptide Delivery Platforms |
~$800M |
12 |
$30M–$200M |
🔥🔥🔥🔥 |
| Cyclic Peptide/Bicyclic Peptide Platforms |
~$1.2B |
10 |
$50M–$555M |
🔥🔥🔥🔥 |
| PDC Peptide-Drug Conjugates |
~$500M |
8 |
$20M–$150M |
🔥🔥🔥 |
| Peptide Vaccines |
~$300M |
6 |
$20M–$150M |
🔥🔥 |
| Antimicrobial Peptides |
~$200M |
5 |
$10M–$50M |
🔥🔥 |
| Cosmetic Peptide Raw Materials |
~$100M |
8 |
$5M–$30M |
🔥 |
| AI-Assisted Peptide Design |
~$150M |
7 |
$5M–$50M |
🔥🔥 |
4. Investment Trend Evolution (2020–2025)
| Year |
Hottest Sector |
Landmark Event |
Capital Preference Shift |
| 2020 |
Peptide vaccines (COVID-19) |
Peptide vaccine R&D boom |
Emergency demand-driven |
| 2021 |
PDC conjugate drugs |
Bicycle IPO + multiple PDC deals |
Technology platform companies favored |
| 2022 |
Cyclic peptide platforms |
Semaglutide blockbuster ignited GLP-1 |
Cyclic peptide tech recognized for FIC potential |
| 2023 |
GLP-1 innovative + generic drugs |
Sciwind IPO, Eccogene Series B |
High-conviction赛道 attracted mega-rounds |
| 2024 |
GLP-1 + oral delivery |
Bicycle $555M follow-on, Rybelsus $2.86B |
Capital concentrated in late-stage |
| 2025 (H1) |
Oral delivery + AI peptide |
Orbital Series A $270M, Circle Series C $95M |
Cross-disciplinary tech rising |
5. Funding Trends (2023→2025)
| Year |
Global Peptide Total Funding |
China Share |
Average Deal Size |
Largest Single Deal |
| 2023 |
~$2.2B |
~18% |
$45M |
Sciwind IPO ($1.2B market cap) |
| 2024 |
~$3.5B |
~22% |
$60M |
Bicycle follow-on ($555M) |
| 2025 (H1) |
~$2.0B |
~25% |
$55M |
Orbital Series A ($270M) |
| Growth Trend |
+59% (2023→2024) |
Rising steadily |
+33% |
— |
Key Findings
- GLP-1 capital magnet: GLP-1-related funding accounts for ~45% of total, shifting toward oral formulations
- China's rising share: China's peptide startup funding share increased from 18% in 2023 to 25% in 2025 H1
- Platform companies favored: Bicyclic peptide platforms (Bicycle), oral delivery platforms (Oramed spin-offs) attracted mega-rounds
- Capital shifting to late-stage: Early seed/Series A deal count declined, but average Series C+ deal size grew 50%
- Cross-disciplinary convergence: Peptide+RNA delivery, peptide+AI design attracting new capital
6. Valuation Analysis
| Valuation Range |
Representative Companies |
Stage |
Core Valuation Drivers |
| $1B+ (Unicorn) |
Bicycle Therapeutics, Zealand Pharma, Sciwind Biosciences |
Listed/Pre-IPO |
Clinical data validation + GLP-1 market ceiling |
| $500M–$1B |
Orbital Therapeutics, Eccogene, Metsera |
Growth stage |
Differentiated technology platform + large partnerships |
| $100M–$500M |
Circle Pharma, Vicinitas, LTD Pharma |
Early–Mid stage |
Proof-of-concept data + team background |
| $50M–$100M |
DingPeptide, Pioneer Peptide |
Series A/B |
Pipeline progress + market opportunity |
| < $50M |
Most early R&D projects |
Seed–Series A |
Scientific team + technology concept |
| Valuation Factor |
Weight |
Description |
| Pipeline Stage |
35% |
Clinical Phase I→II valuation jump of 2–5x |
| Target Market Potential |
25% |
GLP-1赛道 premium is significant |
| Technology Platform Scalability |
20% |
Platform companies valued higher than single-asset |
| Team/Investor Background |
15% |
Top VC backing adds 30–50% premium |
| Existing Partnerships/Milestones |
5% |
BD deals validate commercial value |
7. IPO/M&A Exit Cases
| Company |
Exit Type |
Time |
Amount |
Acquirer/Exchange |
Sector |
| Sciwind Biosciences |
IPO |
2023 |
$1.2B (market cap) |
Nasdaq |
Oral GLP-1 |
| PepGen |
IPO |
2023 |
$108M |
Nasdaq |
Peptide oligonucleotide |
| Bicycle Therapeutics |
Follow-on+BD |
2024 |
$555M |
Nasdaq follow-on |
Bicyclic peptide PDC |
| Ambrx Biopharma |
Acquisition |
2024 |
$2.0B |
Johnson & Johnson |
Peptide conjugate ADC |
| Morphic Therapeutic |
Acquisition |
2024 |
$1.9B |
Eli Lilly |
Oral cyclic peptide integrin |
| Oramed Pharmaceuticals |
Merger |
2023 |
$0.8B |
Reverse merger |
Oral insulin |
| Velocity Pharma |
Acquisition |
2024 |
$0.5B |
Novo Nordisk |
GLP-1 peptide |
| Exit Strategy |
Applicable Conditions |
Expected Return |
Timeline |
| Nasdaq IPO |
Phase II+, $50M+ revenue |
3–10x |
6–10 years |
| HKEX 18A |
China biotech companies |
2–5x |
5–8 years |
| Big Pharma Acquisition |
Differentiated technology / validated data |
4–15x |
4–8 years |
| Reverse Merger (SPAC) |
Fast-track listing need |
2–5x |
3–5 years |
8. Current Hottest Investment Directions
🏆 GLP-1 Biosimilars/Generics
- Driver: Semaglutide China patent expiry in 2026; global generic market projected at $12–15B
- Capital Logic: High certainty (known target + validated market), lower risk than novel targets
- China Representatives: Eccogene, Sciwind Biosciences, Huadong Medicine subsidiaries, etc.
🏆 Oral Delivery Technology
- Driver: Oral semaglutide (Rybelsus) 2024 sales of $2.86B validate market viability
- Differentiation Directions: Next-generation SNAC derivatives, novel polymer carriers, enzyme inhibitor combinations
- Watch: Delivery technology platform companies
🏆 PD-1 Peptide Vaccines
- Driver: Immune checkpoint peptide vaccines entering late-stage clinical trials; potential to overcome traditional vaccine immune response rate bottlenecks
- Capital Focus: Combination strategies of peptide cancer vaccines with checkpoint inhibitors
💰 Funding Data Disclaimer: Funding data on this page is compiled from public press releases, SEC filings, CrunchBase, and industry reports. For reference only and does not constitute investment advice. SENO Biotechnology — Your Peptide R&D and Manufacturing Partner. Visit senopeptide.com/about/ for more industry news and market analysis.